In a challenging year for biotech firms, Ideaya Biosciences Inc . (NASDAQ:IDYA) stock has reached a 52-week low, touching down at $21.02. According to InvestingPro data, the company maintains strong ...

MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the initiation of VALUE, a global, pivotal Phase III trial evaluating ...

Royalty Pharma to provide R&D investment of up to $250 million for Biogen's litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus. NEW ...

For tech startups, the path from innovation to market success often presents a critical challenge: transforming deep ...

From Software details delivering a new type of gameplay built from the bones of a familiar one.

Prior to this call, DoubleDown issued its financial results for the fourth quarter of 2024 in a press release, a copy of which is available in the Investor Relations section of the company's website ...

Discover how the six-week sprint model reshapes product development, eliminating backlogs, encouraging rapid iteration and ...

DealHub.io, the leading Revenue AI platform, today announced a strategic leadership transition to drive its next phase of ...

Some key cybersecurity and technology executives, including CTO Raghu Bongula, are out at ConnectWise amid leadership changes within its product and engineering teams.

From private capital mobilization, to MDBs, a key question in a year that features a pivotal Fourth International Conference ...

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug NV-387, a drug that the Bird Flu ...

Our fair value estimate for Monday is $332 per share. This implies a fiscal 2025 adjusted price/earnings ratio of 94 times and a fiscal 2025 enterprise value/sales of 13. Our discounted cash flow ...